Acumen Pharmaceuticals, Inc. (ABOS) Stock Price & Analysis
Acumen Pharmaceuticals, Inc. (ABOS) fell 1.84% to USD 2.13 as of July 25, 2026 at 06:40 UTC, according to Nexqual real-time market data.
ABOS last closed at USD 2.17; the session ranged USD 2.12–2.2 on volume of 226,088 shares. Market capitalization is $153.84M, with a 52-week range of USD 1.19–3.6 (NMS). Source: Nexqual, July 25, 2026 at 06:40 UTC.
Key Statistics (as of July 25, 2026 at 06:40 UTC)
| Price | USD 2.13 |
|---|---|
| Change | ▼ 1.84% (down) |
| Previous Close | USD 2.17 |
| Open | USD 2.2 |
| Day Range | USD 2.12 – 2.2 |
| 52-Week Range | USD 1.19 – 3.6 |
| Volume | 226,088 shares |
| Market Cap | $153.84M |
| Exchange | NMS |
Technical Analysis (ABOS)
Nexqual's technical model rates ABOS "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.06 (neutral) |
| vs SMA50 | Below (USD 2.39) |
| MACD | -0.08 (negative) |
Analyst Ratings (ABOS)
Wall Street analysts rate ABOS "Strong Buy" based on 5 analysts, with a mean price target of USD 7.4 (range USD 4–10), per Nexqual as of July 25, 2026 at 06:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7.4 |
| High Target | USD 10 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ABOS)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.41 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.33 vs est -0.46 ▲ beat |
| 2025-12-31 | USD -0.41 vs est -0.56 ▲ beat |
| 2025-09-30 | USD -0.44 vs est -0.68 ▲ beat |
| 2025-06-30 | USD -0.68 vs est -0.52 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
Financials & Fundamentals (ABOS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -93.23% |
| Debt / Equity | 35.62 |
| Current Ratio | 4.55 |
| Total Cash | $128.40M |
| Total Debt | $31.16M |
| Free Cash Flow | $-67.43M |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
Financial Health Score (ABOS)
Nexqual rates Acumen Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $128M cash vs $31M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$106M |
| Efficiency | Critical — ROE -93%, ROA -42.4% |
Ownership (ABOS)
| Insider Ownership | +6.80% |
|---|---|
| Institutional Ownership | +64.63% |
| Shares Outstanding | 72.23M |
| Float | 36.96M |
| Short % of Float | +5.59% |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
Leadership (ABOS)
Acumen Pharmaceuticals, Inc. is led by Daniel J. O'Connell (age 55), CEO & Director, per Nexqual as of July 25, 2026 at 06:40 UTC.
| CEO & Director | Daniel J. O'Connell (age 55) |
|---|---|
| President & Chief Development Officer | James Doherty (age 57) |
| CFO & Chief Business Officer | Matt Zuga |
| Chief Operating Officer | Russell Barton M.S. (age 66) |
| Senior Vice President of Finance & Accounting and Corporate Controller | Kelly Carranza |
Major Backers & Investors (ABOS)
Notable institutional backers of Acumen Pharmaceuticals, Inc. include RA Capital Management, L.P., Sands Capital Alternatives, LLC, Alyeska Investment Group, L.p., according to Nexqual as of July 25, 2026 at 06:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 29.06% |
| Sands Capital Alternatives, LLC | 5.15% |
| Alyeska Investment Group, L.p. | 3.4% |
| Franklin Resources, Inc. | 3.19% |
| Adar1 Capital Management, LLC | 2.99% |
| Knollwood Investment Advisory, LLC | 2.25% |
| FMR, LLC | 1.6% |
| Ikarian Capital, LLC | 1.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.13% |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
From Acumen Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
- It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
- Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co.
- Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc. | USD 2.03 | ▲ 0.5% |
| JBIO | Jade Biosciences, Inc. | USD 20.08 | ▲ 1.16% |
| ABVC | ABVC Biopharma, Inc. | USD 1.15 | ▼ 2.54% |
| ACXP | Acurx Pharmaceuticals, Inc. | USD 1.42 | ▼ 3.4% |
| ANNX | Annexon, Inc. | USD 5.22 | ▼ 0.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:40 UTC. This page is informational and not investment advice.